Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

's Biography



, ,

I am a professor of Radiology and Radiation Oncology at Thomas Jefferson University in Philadelphia. I am also the Director of the laboratories of Radiopharmaceutical research and Molecular Imaging. I obtained my MS and PhD degrees from the University London, England. The major thrust of my research is to develop radiopharmaceuticals for diagnostic and therapeutic applications. I have published more than 500 original articles, review papers, book chapters, abstracts, and editorials. I have also published four books and translated my basic research into clinical applications. I have given numerous invited presentations at home and abroad, in academic institutions and industries, and at national and international scientific gatherings. I hold 20 granted patents and serve on the editorial board for 14 journals. As a PI and Co-PI, my research has always been funded by federal, foundational, and industrial grants. Currently I hold three INDs from the US FDA to perform clinical research. My contributions to the field of nuclear medicine and molecular imaging is well recognized by my peers, for which I have received 10 national and International awards, including the Society of Nuclear Medicine’s highest honor, the Benedict Cassen award. I have been elected as President of three international societies, including the Society of Nuclear Medicine and Molecular Imaging.

  Image

Optical Imaging of Genitourinary Cancer: A Biofluid Assay

Tuesday, 17 November 2015 at 14:00

Add to Calendar ▼2015-11-17 14:00:002015-11-17 15:00:00Europe/LondonOptical Imaging of Genitourinary Cancer: A Biofluid AssaySELECTBIOenquiries@selectbiosciences.com

Non-invasive diagnosis of genitourinary cancer continues to be challenging.  In recent years detecting circulating tumor cells (CTC) in peripheral blood has emerged as one of the most sought-after fields.  CTC determination can assess the presence of primary disease, determine effectiveness of therapy and predict disease recurrence.  Current approaches for determination of CTC for genitourinary cancer ,however, are time consuming, complex and are not yet widely used in clinical practice.  Genitourinary cancer cells express on their surface a genomic biomarker VPAC1, in high density, prior to elevation of PSA and alternations in cell morphology.  These cells are shed (STC) in urine.  We hypothesize that targeting VPAC1 receptors using a receptor specific biomolecule TP4303, developed in our laboratory, will permit us to detect STC accurately and non-invasively.


Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com